Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
1. Phase 2b study of SPN-820 failed to meet primary endpoint for depression. 2. No significant difference between SPN-820 and placebo was found. 3. Safety profile for SPN-820 remains consistent with past trials. 4. Onapgo injection approved, set for market in Q2 2025. 5. SUPN stock down 14.10% following trial results.